Hyperphosphatemia Pipeline Insight

DelveInsight’s, “Hyperphosphatemia - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Hyperphosphatemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Hyperphosphatemia Understanding

Hyperphosphatemia: Overview

Hyperphosphatemia—that is, abnormally high serum phosphate levels—can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. However, even severe hyperphosphatemia is for the most part clinically asymptomatic. Morbidity In patients with this condition is more commonly associated with an underlying disease than with increased phosphate values.

 

"Hyperphosphatemia - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperphosphatemia pipeline landscape is provided which includes the disease overview and Hyperphosphatemia treatment guidelines. The assessment part of the report embraces, in depth Hyperphosphatemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hyperphosphatemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hyperphosphatemia R&D. The therapies under development are focused on novel approaches to treat/improve Hyperphosphatemia.

Hyperphosphatemia Emerging Drugs Chapters

This segment of the Hyperphosphatemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Hyperphosphatemia Emerging Drugs

 

FC818 (ferric citrate): PUMC Pharmaceutical

FC818 is a novel non-calcium-based phosphate binder. One Phase I and two pivotal Phase II clinical trials showed FC818 to be an effective and safe treatment for lowering and/or maintaining serum phosphorus levels <5.5 mg/dL in ESRD patients with hyperphosphatemia. The drug is currently in phase III of clinical trial for the treatment of Hyperphosphataemia.

 

VS 505: Shanghai Alebund Pharmaceuticals

VS 505 is a phosphate binding modulator being developed by Shanghai Alebund Pharmaceuticals for the treatment of Hyperphosphataemia. The drug is currently in phase II of clinical trials.

Further product details are provided in the report……..

Hyperphosphatemia: Therapeutic Assessment

This segment of the report provides insights about the different Hyperphosphatemia drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Hyperphosphatemia

There are approx. 15+ key companies which are developing the therapies for Hyperphosphatemia. The companies which have their Hyperphosphatemia drug candidates in the most advanced stage, i.e. phase III include, PUMC Pharmaceutical.

Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Hyperphosphatemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hyperphosphatemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hyperphosphatemia therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperphosphatemia drugs.

Hyperphosphatemia Report Insights

  • Hyperphosphatemia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Hyperphosphatemia Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Hyperphosphatemia drugs?
  • How many Hyperphosphatemia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperphosphatemia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hyperphosphatemia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hyperphosphatemia and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Hyperphosphatemia: Overview

  • Causes
  • Mechanism of Action 
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type 

Hyperphosphatemia – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Hyperphosphatemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Hyperphosphatemia Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

FC 818: PUMC Pharmaceutical

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Mid Stage Products (Phase II) 

  • Comparative Analysis

VS 505: Shanghai Alebund Pharmaceuticals

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Hyperphosphatemia Key Companies

Hyperphosphatemia Key Products

Hyperphosphatemia- Unmet Needs

Hyperphosphatemia- Market Drivers and Barriers

Hyperphosphatemia- Future Perspectives and Conclusion

Hyperphosphatemia Analyst Views

Hyperphosphatemia Key Companies

Appendix

List of Table

Table 1: Total Products for Hyperphosphatemia

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Hyperphosphatemia

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• PUMC Pharmaceutical
• Shanghai Alebund Pharmaceuticals
• Ardelyx
• Kyowa Kirin
• Phosphate Therapeutics
• Liaoning Grand Nuokang Biopharmaceutical Co., Ltd.
• Chugai Pharmaceutical
• Keryx Biopharmaceuticals
• Panion & BF Biotech Inc.
• Sinomune Pharmaceutical
• Daiichi Sankyo
• J-Pharma
• OPKO Renal
• Altair Nanotechnologies
• China Nuokang Bio-Pharmaceutical
• Unicycive Therapeutics

 

Forward to Friend

Need A Quote